These are routine director interest notices with no trading signal. Monitor upcoming 6-K filings for any material updates on the ATH434 Phase 3 program or capital raise activities, which are the primary value drivers for this pre-revenue biotech.
Price Chart
Executive Summary
Alterity Therapeutics filed two 6-Ks on September 2, 2026, each reporting a change in director's interest notice (one for Director Stamler, one for Director Marks). These are routine administrative filings disclosing changes in director shareholdings, with no material financial or operational information provided. The filings are neutral and do not alter the company's fundamental outlook, which remains tied to its cash runway and the progress of its lead candidate ATH434 towards a Phase 3 registrational program in Multiple System Atrophy (MSA).
Key Facts
- Two separate 6-K filings were submitted on September 2, 2026.
- Each filing contains a Change of Director's Interest Notice (Exhibit 99.1) for a director: Stamler and Marks.
- No financial figures, operational updates, or strategic changes were disclosed in the filings.
- The filings are routine and administrative in nature.
Financial Impact
No financial impact from these filings.
Risk Factors
- No new risks identified from these filings. The company's existing risks (going concern, need for capital, clinical trial failure) remain unchanged.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (ATHE) — Batch item 1 | 0001437749-26-029450 |
| Document: 0001437749-26-029450-index-headers.html | 0001437749-26-029449 |
| Document: 0001437749-26-029450-index.html | 0001437749-26-029450 |
| Document: 0001437749-26-029450.txt | 0001437749-26-029450 |
| 6-K Filing (ATHE) — Batch item 5 | 0001437749-26-029449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers